Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Breast cancer symbols : PFE save search
Global Panic Disorders Market Insights | Size | Shares | Trends | Growth | Industry Analysis [2020-2030] Panic disorders, also known as anxiety disorder deals with recurrent and unexpected panic attacks. PET-CT Scanner Devices Market: Competitive Landscape Analysis With Forecast by 2031 Wilmington, Delaware: According to the report, the global PET-CT scanner devices market was valued over US$ 200 Mn in 2020 and is projected to expand at a CAGR of ~3% from 2021 to 2031. Portal Hypertension Market Insights | Current Trends | Growth Opportunity | Global Industry Analysis [2020-2030] At present, treatment options for portal hypertension is limited due to the dearth of approval of specialized drugs. Spatial Genomics & Transcriptomics Market to Experience Significant Growth by 2027 Wilmington, Delaware: The spatial genomics & transcriptomics market is prognosticated to bring profitable growth during the assessment period of 2019-2027. Teleradiology Services Market to Make Great Impact in Near Future by 2031 Wilmington, Delaware: According to the report, the global teleradiology services market was valued over US$ 6.4 Bn in 2020. Anti-depressants Drugs and Therapies Market to Witness a Pronounce Growth by 2025 Wilmington, Delaware: Anti-depressants medications lower the symptoms of depression, dysthymia, chronic depression, and anxiety disorders. B-Cell Non-Hodgkin’s Lymphoma (NHL) Market to Offer Ample Growth Opportunities by 2027 Wilmington, Delaware: Non-Hodgkin’s lymphoma is a group of heterogeneous proliferative malignancies. Heightening Healthcare Spending Opening Growth Avenues for Collateral Ligament Stabilizer System Market, Reaching US$ 3.5 Billion in 2032: Fact.MR Study Fact.MR – A Market Research and Competitive Intelligence Provider: The global collateral ligament stabilizer system market is expected to reach US$ 3.5 Billion by the end of the 2022-2032 forecast period, growing at a CAGR of 6.1%, concludes a recently published report by Fact.MR. Breast Cancer Liquid Biopsy Market Trends, Growth, Analysis and Future Scope, 2026 Wilmington, Delaware: A biopsy is a tissue or cell sample taken from any part of the patient’s body and examined in the lab for the detection of cancer. Cerebral Palsy Market Size, Shares, Trends and Growth | Global Industry Analysis [2020-2030] The global cerebral palsy market is picking up steam due to increasing awareness about the condition amongst parents. Continuous Glucose Monitoring Market: Competitive Research and Precise Outlook 2021 to 2028 Wilmington, Delaware: The global continuous glucose monitoring market depicts the presence of a large competitive vendor landscape, says Transparency Market Research on the basis of a newly research report. Crow’s Feet Market Key Trends and Opportunity Analysis up to 2026 Albany NY, United States: The demand within the global crow’s feet market has been escalating on account of vital advancements in the field of dermatology in recent times. HIV Associated Lipodystrophy Syndrome Market Insights | Global Industry Analysis [2020-2030] HIV-associated lipodystrophy is a syndrome that are found in human immune-deficiency virus -infected patients who are being administered with active antiretroviral medications for the treatment of HIV infection. Global Mail Service Pharmacy Market | Size | Shares | Trends | Growth | Forecast [2020-2030]
Published: 2022-06-03 (Crawled : 06:00) - biospace.com/
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -1.55%
H: 0.0%
C: 0.0%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.94%
H: 0.0%
C: 0.0%
AZNCF | $138.24 -4.19% 800
|
Health Technology
|
| O: -0.4%
H: 4.05%
C: -1.35%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: 0.0%
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -2.25%
H: 0.0%
C: 0.0%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -1.4%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: 0.0%
NBIX M | $132.03 -0.39% -0.39% 560K
|
Health Technology
|
| O: 2.29%
H: 0.0%
C: 0.0%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.56%
H: 0.82%
C: -0.64%
lipodystrophy treatment research system active services report service growing hiv profitable hypertension genomics expected virus approval cancer growth group market breast cancer infections
Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019
Published: 2022-01-14 (Crawled : 17:00) - prnewswire.com
AZNCF | $138.24 -4.19% 800
|
Health Technology
|
| O: -0.21%
H: 0.98%
C: 0.98%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -1.01%
H: 0.0%
C: 0.0%
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 0.65%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.17%
H: 0.0%
C: 0.0%
treatment cancer breast cancer merge
Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
Published: 2021-12-10 (Crawled : 13:30) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.52%
H: 0.0%
C: 0.0%
ARVN | $34.78 1.43% 1.41% 940K
|
Health Technology
|
| O: -2.1%
H: 0.0%
C: 0.0%
arv-471 protac cancer breast cancer her2- her2
Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium
Published: 2021-11-19 (Crawled : 15:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.84%
H: 0.0%
C: 0.0%
ARVN | $34.78 1.43% 1.41% 940K
|
Health Technology
|
| O: 0.34%
H: 5.88%
C: 4.6%
phase 1 cancer breast cancer symposium
Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer
Published: 2021-04-08 (Crawled : 21:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.14%
H: 0.53%
C: 0.0%
CELC | $17.22 5.06% 4.82% 230K
|
Commercial Services
|
| O: -1.04%
H: 0.42%
C: 0.42%
cancer breast cancer commercialization license
Real-World Evidence Supports Effectiveness of First-line IBRANCE® (palbociclib) Combination Therapy in HR+, HER2- Metastatic Breast Cancer
Published: 2021-03-25 (Crawled : 12:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.11%
H: 0.39%
C: 0.06%
therapy cancer breast cancer her2+ her2- her2 metastatic breast cancer
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.